Background: Osteoarthritis is a chronic disorder that affects the synovial joints by the progressive loss of articular cartilage. In the hip, the largest weight-bearing joint, the deterioration of articular cartilage and acetabular labrum can cause pain, diminishing the quality of life for patients. This study presents changes in reported pain scales from patients who received Wharton’s jelly applications to cartilage deterioration in the hip from the observational retrospective repository at Regenative Labs. Methods: Sixty-nine patients were selected based on inclusion criteria with patient-reported pain scales, including the Numeric Pain Rating Scale and the Western Ontario and McMaster University Osteoarthritis Index, collected at the initial application, 30, and 90-day follow-up visits. Thirteen patients received a second allograft application and had additional follow-up visits at 120 and 180 days. Results: Five of the six scales used showed a statistically significant improvement in average scores across the cohort. The greatest improvements were observed in the NPRS with a 31.36% improvement after 90 days and a 44.64% improvement for patients with two applications after 180 days. The minimal clinically important difference (MCID) was also calculated to determine the perceived value of care for each patient with 44.9% of patients exceeding the MCID and 78.3% reporting at least one level of improvement. Conclusions: The positive outcomes for the patients in this cohort suggest WJ to be a promising alternative care option for patients with structural tissue degeneration in the hip refractory to the current standard of care.
With the increasing occurrence of rotator cuff injuries every year, there is a great need for a reliable treatment option. Wharton’s Jelly contains several components that can positively impact the replacement and repair of musculoskeletal defects. The overall objective of this study is to evaluate the improvement of patient-reported pain scales after applying Wharton’s Jelly (WJ) in rotator cuff defects. Eighty-seven patients with rotator cuff defects who failed at least eight weeks of conservative treatment were selected from the retrospective repository. A total of 2 cc of WJ flowable allograft was applied to the specific affected anatomy, the most common being supraspinatus tendon, biceps tendon insertion, labral tear, and subscapularis tear. No adverse reactions were reported. Statistically significant improvements were found from the initial to Day 90 in all scales. Patient satisfaction was calculated using minimal clinically important differences. No statistically significant differences were found in mean changes between gender, BMI, and age. Scanning electron microscopy images reveal the similarities between the collagen matrix in WJ and the rotator cuff. The significant improvement in patient outcomes coincides with the current literature analyzing WJ applications with other structural defects around the body. WJ is a promising alternative for musculoskeletal defects when the standard of care fails.
With the increasing occurrence of rotator cuff injuries every year, there is a great need for a reliable treatment option. Wharton’s Jelly contains several components that can positively impact the replacement and repair of musculoskeletal defects. The overall objective of this study is to evaluate the improvement of patient-reported pain scales after applying Wharton’s Jelly (WJ) in rotator cuff defects. Eighty-seven patients with rotator cuff defects who failed at least eight weeks of conservative treatment were selected from the retrospective repository. 2cc of WJ flowable allograft was applied to the specific affected anatomy, the most common being supraspinatus tendon, biceps tendon insertion, labral tear, and subscapularis tear. No adverse reactions were reported. Statistically significant improvements were found from the initial to Day 90 in all scales. Patient satisfaction was calculated using minimal clinically important differences. No statistically significant differences were found in mean changes between gender, BMI, and age. Scanning Electron Microscopy images reveal the similarities between the collagen matrix in WJ and the rotator cuff. The significant improvement in patient outcomes coincides with current literature analyzing WJ applications with other structural defects around the body. WJ is a promising alternative for musculoskeletal defects when the standard of care fails.
Introduction: Plantar fasciitis (PF), or more recently plantar fasciopathy due to its degenerative nature, is the most common cause of heel pain in adults and is often refractory to conservative care. One alternative conservative intervention involves replacing damaged fascia with homologous tissue, such as Wharton’s jelly (WJ) connective tissue allografts. The purpose of this observational study is to evaluate the efficacy and safety of collagen-rich Wharton’s jelly (WJ) when applied to defects in the plantar fascia. Materials and Methods: From the observational repository, nine patients who had plantar fasciopathy and received a single application of WJ were observed over 90 days. Outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality-of-Life Scale (QOLS) with no adverse reactions reported. Results: The cohort was 56% male (n = 5) and 44% female (n = 4), with a mean age of 73. From the initial to final visit, patients reported an overall trend of improvement in all scales. Statistically significant Bonferroni-adjusted differences were observed in the WOMAC scale. Age was a significant predictor of the total WOMAC score change from the initial to the final visit. Discussion: Although only a small cohort was observed, the preliminary evidence suggests the safety and efficacy of WJ allografts for plantar fascia degeneration. Key limitations of this study included a small cohort size and a lack of a comparison group with other alternative methods. Conclusions: The favorable results in this study could encourage future research to validate the clinical potential, safety, and dosing protocols of Wharton’s jelly as a primary conservative care method for patients suffering from plantar fasciopathy.
Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue and causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTAs) have a collagen-rich matrix with various extracellular matrix (ECM) components that can replace damaged connective tissue. The objective of this paper is to analyze the preliminary findings from an observational repository on UCTAs for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods through patient-reported scales. Materials and Methods: A total of 117 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTAs; outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality-of-Life Scale (QOLS). Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group, non-standardized application protocol, and the increase in recall and response bias due to using patient-reported measures. Conclusions: This pilot investigation presents the preliminary effectiveness necessary in hypothesis generation for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTAs to other conservative interventions.
Introduction: Cervical paraspinal enthesopathy is characterized by fatty infiltration and muscle degeneration; current methods only provide symptomatic relief or involve significant postoperative complications. This study provides preliminary results for the clinical potential of umbilical cord tissue allografts (UCTa) in patients with cervical paraspinal enthesopathy and degeneration refractory to standard care. Materials and Methods: The Numeric Pain Rating Scale, Western Ontario and McMaster University Arthritis Index, and Quality of Life Scale were used to measure outcomes of thirty-one patients with cervical paraspinal degeneration from an observational repository who received one to three UCT allograft applications. The Wilcoxon Signed-Rank test, Mann-Whitney U test, and Jonckheere-Terpstra test were performed for the analysis. Results: Substantial percentage improvements were observed from the patient cohort, with the triple application group reporting the highest percentage improvement. Statistically significant differences were presented in all application groups. No adverse events were reported. Discussion: This study provided preliminary findings that UCTas are a safe, minimally invasive application for cervical paraspinal defects. Notable limitations included a lack of a direct comparison group and a small sample size. Conclusion: This study highlights the need for continued research to validate the preliminary results for the safety, feasibility, and efficacy of umbilical cord tissue allografts in patients with cervical paraspinal defects.